Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797212 | 0.83 | SMN1; SMN2 (0.49) | TSPOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11052886 | 0.81 | ALDH1A1 (0.46) | PTPN7SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL690247 | 0.81 | ALDH1A1 (0.53) | TSPOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28758819 | 0.80 | UTS2R (0.46) | PTPN7SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL7191809 | 0.80 | ALDH1A1 (0.41) | PTPN7SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL8852613 | 0.80 | INSR (0.49) | PTPN7SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL10539922 | 0.79 | ALDH1A1 (0.52) | TSPOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10536986 | 0.79 | ALDH1A1 (0.52) | TSPOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11883247 | 0.78 | TSHR (0.47) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6905494 | 0.77 | KDM4E (0.43) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078436-A1 | Process for the catalytic preparation of N-acylglycine derivatives | GEISSLER HOLGER (DE) | 2003-04-24 | — | — | US | disclosed |
| EP-0918745-B1 | CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-28 | — | — | EP | disclosed |
| US-20010007911-A1 | CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES | AVENTIS RESEARCH & TECHNOLOGIES DEUTCHLAND GMBH & CO. KG. (DE) | 2001-07-12 | — | — | US | disclosed |
| CN-1228078-A | Catalytic preparation process of N-acylglycine derivatives | AWENTIS RESEARCH & TECHNOLOGY (DE) | 1999-09-08 | — | — | CN | disclosed |
| EP-0918745-A1 | CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES | Aventis Research & Technologies GmbH & Co KG (DE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998004518-A1 | CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007911-A1 | CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES | ACACA, ACOX1, APEH | PTPN7 4509/4885TSPO 3555/4885SMN1; SMN2 3157/4885 |
| US-20030078436-A1 | Process for the catalytic preparation of N-acylglycine derivatives | GNMT, ALKBH3, DDC | PTPN7 3795/4885TSPO 3314/4885SMN1; SMN2 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.